바이오로직스 자료
Reducing ADC timelines with integrated development and manufacturing services
Antibody-Drug Conjugates (ADCs) consist of different elements requiring specialized capabilities during the manufacturing process. Given the complexity of their development and manufacturing, accelerating timelines becomes a pivotal success factor for the ADC market.
In this whitepaper, Thomas Rohrer, Senior Director of Technical Support Bioconjugates, delves into how integrating development and production activities within a single outsourcing partner can dramatically streamline ADC development timelines and mitigate risks.
Antibody-Drug Conjugates (ADCs) consist of different elements requiring specialized capabilities during the manufacturing process. Given the complexity of their development and manufacturing, accelerating timelines becomes a pivotal success factor for the ADC market.
In this whitepaper, Thomas Rohrer, Senior Director of Technical Support Bioconjugates, delves into how integrating development and production activities within a single outsourcing partner can dramatically streamline ADC development timelines and mitigate risks.